Enzo Biochem (ENZ) 10-Q 12 Mar 15 2015 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jan. 31, 2015	Mar. 02, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-Q
Current Fiscal Year End Date	-24
Entity Common Stock, Shares Outstanding		45,374,000
Amendment Flag	FALSE
Entity Central Index Key	316253
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Jan-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jan. 31, 2015	Jul. 31, 2014
In Thousands, unless otherwise specified
ASSETS
Cash and cash equivalents	$15,346	$17,455
Accounts receivable, net of allowances	11,795	12,470
Inventories	8,283	8,690
Prepaid expenses and other	1,593	2,121
Total current assets	37,017	40,736
Property, plant and equipment, net	7,567	7,730
Goodwill	7,452	7,452
Intangible assets, net	7,122	8,108
Other assets	385	385
Total assets	59,543	64,411
LIABILITIES AND STOCKHOLDERS’ EQUITY
Loan payable	3,013	3,013
Accounts payable – trade	6,840	8,245
Accrued liabilities	12,007	12,917
Other current liabilities	830	790
Total current liabilities	22,690	24,965
Deferred taxes	119	183
Other liabilities	1,872	2,313
Total liabilities	24,681	27,461
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 45,374,074 at January 31, 2015 and 44,239,183 at July 31, 2014	454	443
Additional paid-in capital	322,738	317,160
Accumulated deficit	-290,217	-282,397
Accumulated other comprehensive income	1,887	1,744
Total stockholders’ equity	34,862	36,950
Total liabilities and stockholders’ equity	$59,543	$64,411

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Jan. 31, 2015	Jul. 31, 2014
Preferred Stock, par value (in Dollars per share)	$0.01	$0.01
Preferred Stock, shares authorized	25,000,000	25,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$0.01	$0.01
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	45,374,074	44,239,183
Common Stock, shares outstanding	45,374,074	44,239,183

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014
Revenues:
Clinical laboratory services	$14,725	$13,848	$30,547	$28,707
Product revenues	7,723	8,054	15,725	15,717
Royalty and license fee income	644	1,026	1,644	2,637
Total revenues	23,092	22,928	47,916	47,061
Operating expenses:
Cost of clinical laboratory services	9,246	9,292	19,376	19,001
Cost of product revenues	3,818	3,865	7,513	7,712
Research and development	834	832	1,625	1,649
Selling, general, and administrative	9,670	10,084	19,955	20,612
Provision for uncollectible accounts receivable	601	912	1,142	1,784
Legal fee expense	2,804	1,496	5,270	2,877
Total operating expenses	26,973	26,481	54,881	53,635
Operating loss	-3,881	-3,553	-6,965	-6,574
Other income (expense):
Interest	-49	-52	-118	-114
Other	-17	15	2	76
Foreign exchange (loss) gain	-259	20	-731	317
Loss before income taxes	-4,206	-3,570	-7,812	-6,295
Benefit (provision) for income taxes	115	4	-8	-58
Net loss	($4,091)	($3,566)	($7,820)	($6,353)
Net loss per common share:
Basic and diluted (in Dollars per share)	($0.09)	($0.09)	($0.17)	($0.15)
Weighted average common shares outstanding:
Basic and diluted (in Shares)	45,000	41,887	44,782	41,472

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014
Net loss	($4,091)	($3,566)	($7,820)	($6,353)
Other comprehensive income (loss):
Foreign currency translation adjustments	35	-47	143	-91
Comprehensive loss	($4,056)	($3,613)	($7,677)	($6,444)

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
In Thousands, except Share data
Balance at Jul. 31, 2014	$443	$317,160	($282,397)	$1,744	$36,950
Balance (in Shares) at Jul. 31, 2014	44,239,183
Net loss for the period ended January 31, 2015			-7,820		-7,820
Vesting of restricted stock (in Shares)	8,087
Share-based compensation charges		203			203
Net proceeds from issuance of common stock (net of expenses of $169)	11	5,330			5,341
Net proceeds from issuance of common stock (net of expenses of $169) (in Shares)	1,126,804
Amortization of options in lieu of payment of cash bonuses		45			45
Foreign currency translation adjustments				143	143
Balance at Jan. 31, 2015	$454	$322,738	($290,217)	$1,887	$34,862
Balance (in Shares) at Jan. 31, 2015	45,374,074

CONSOLIDATED_STATEMENT_OF_STOC1

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parentheticals) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015
Issuance of common stock, expenses	$169
Common Stock [Member]
Issuance of common stock, expenses	169
Additional Paid-in Capital [Member]
Issuance of common stock, expenses	$169

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014
Cash flows from operating activities:
Net loss	($7,820)	($6,353)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment	1,014	1,099
Amortization of intangible assets	859	928
Provision for uncollectible accounts receivable	1,142	1,784
Deferred income tax benefit	-48	-50
Share-based compensation charges	203	212
Accrual for share-based 401(k) employer match expense	296	319
Foreign exchange loss (gain)	570	-319
Changes in operating assets and liabilities:
Accounts receivable	-524	-1,333
Inventories	306	-381
Prepaid expenses and other	524	512
Accounts payable – trade	-1,423	345
Accrued liabilities, other current liabilities and other liabilities	-1,571	-1,467
Total adjustments	1,348	1,649
Net cash used in operating activities	-6,472	-4,704
Cash flows from investing activities:
Capital expenditures	-653	-444
Security deposits and other		-28
Net cash used in investing activities	-653	-472
Cash flows from financing activities:
Net proceeds from issuance of common stock	5,341	4,244
Proceeds from borrowings under Credit Agreement	43,362	36,614
Repayments under Credit Agreement	-43,362	-36,965
Installment loan and capital lease obligation payments	-230	-181
Net cash provided by financing activities	5,111	3,712
Effect of exchange rate changes on cash and cash equivalents	-95	78
Decrease in cash and cash equivalents	-2,109	-1,386
Cash and cash equivalents - beginning of period	17,455	9,007
Cash and cash equivalents - end of period	$15,346	$7,621

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jan. 31, 2015
Disclosure Text Block [Abstract]
Basis of Accounting [Text Block]	Note 1 – Basis of Presentation
	The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively referred to as the “Company” or “Companies”. The consolidated balance sheet as of January 31, 2015, the consolidated statements of operations and the consolidated statements of comprehensive income (loss) for the three and six months ended January 31, 2015 and 2014, the consolidated statements of cash flows for the six months ended January 31, 2015 and 2014, and the consolidated statement of stockholders’ equity for the six months ended January 31, 2015 are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2014 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2014 has been derived from the audited financial statements at that date. The results of operations for the three and six months ended January 31, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2015.

Net_loss_per_share

Net loss per share	6 Months Ended
	Jan. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 2 – Net loss per share
	Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. The dilutive effect of potential common shares if any, consisting of outstanding stock options and unvested restricted stock is determined using the treasury stock method. Diluted weighted average shares outstanding for the three and six months ended January 31, 2015 and 2014, as a result of the net loss for each period, do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive, and as such is the same as basic weighted average shares outstanding.
	During the three and six months ended January 31, 2015, potential shares from unvested restricted stock excluded from the computation of diluted net loss per share were approximately zero and 18,000 shares, respectively. During the three and six months ended January 31, 2014, potential shares from unvested restricted stock excluded from the computation of diluted net loss per share were approximately zero and 22,000 shares, respectively.
	For the three and six months ended January 31, 2015, potential shares for “in the money” stock options excluded from the computation of diluted net loss per share were approximately 411,000 and 438,000 shares, respectively. For the three and six months ended January 31, 2014, there were 0 potential shares for “in the money” stock options excluded from the computation of diluted net loss per share.
	For the three and six months ended January 31, 2015 the effect of approximately 52,000 and 97,000 shares respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. For the three and six months ended January 31, 2014 the effect of approximately 1,341,000 and 1,032,000 shares respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.

Supplemental_disclosure_for_st

Supplemental disclosure for statement of cash flows	6 Months Ended
	Jan. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Note 3 - Supplemental disclosure for statement of cash flows
	For the six months ended January 31, 2015 and 2014, income taxes paid by the Company were $37 and $17, respectively.
	For the six months ended January 31, 2015 and 2014, interest paid by the Company was $101 and $98, respectively.
	For the six months ended January 31, 2015 and 2014, the Company financed $57 and $154 respectively, in machinery and transportation equipment under installment loans.
	During the six months ended January 31, 2015, there was a total of $155 in capital lease agreements. During the six months ended January 31, 2014, the Company did not enter into any capital lease agreements.
	During the six months ended January 31, 2015, the Company recorded $45 in additional paid in capital and reduced accrued liabilities by the same amount for options previously issued in lieu of cash payment of certain incentive compensation awards.

Inventories

Inventories	6 Months Ended
	Jan. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 - Inventories
	Inventories consist of the following:
		January 31,		July 31,
		2015		2014
	Raw materials	$	1,086	$	1,092
	Work in process		2,285		2,460
	Finished products		4,912		5,138
		$	8,283	$	8,690

Goodwill_and_intangible_assets

Goodwill and intangible assets	6 Months Ended
	Jan. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Note 5 – Goodwill and intangible assets
	At January 31, 2015 and July 31, 2014, the Company’s net carrying amount of goodwill, related to the Clinical Labs segment, is $7,452.
	The Company’s change in the net carrying amount of intangible assets, all of which is included in the Life Sciences segment is as follows:
		Gross			Accumulated			Net
					Amortization
	31-Jul-14	$	28,478		$	(20,370	)	$	8,108
	Amortization expense		—			(859	)		(859	)
	Foreign currency translation		(442	)		315			(127	)
	31-Jan-15	$	28,036		$	(20,914	)	$	7,122
	Intangible assets consist of the following:
		31-Jan-15									31-Jul-14
		Gross			Accumulated			Net			Gross		Accumulated			Net
					Amortization								Amortization
	Patents	$	11,027		$	(10,793	)	$	234		$	11,027	$	(10,775	)	$	252
	Customer relationships		12,343			(6,943	)		5,400			12,602		(6,565	)		6,037
	Website and acquired content		1,027			(1,027	)		—			1,037		(1,037	)		—
	Licensed technology and other		511			(422	)		90			537		(434	)		103
	Trademarks		3,128			(1,729	)		1,398			3,275		(1,559	)		1,716
	Total	$	28,036		$	(20,914	)	$	7,122		$	28,478	$	(20,370	)	$	8,108
	At January 31, 2015, information with respect to intangibles assets acquired is as follows:
			Useful life				Weighted average
			assigned				remaining useful life
			Years
	Customer relationships		8		15		5.5 years
	Trademarks					5	2.5 years
	Other intangibles		4		5		0.5 year
	At January 31, 2015, the weighted average useful life of amortizable intangible assets is approximately 4.5 years.

Loan_Payable

Loan Payable	6 Months Ended
	Jan. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 6 - Loan Payable
	On June 7, 2013, the Company entered into a secured Revolving Loan and Security Agreement (the “Credit Agreement”) among the Company and certain of its subsidiaries, with Enzo Therapeutics as a guarantor, and Healthcare Finance Group, LLC (the “Lender).The Credit Agreement, which expires in December 2016, provides for borrowings against eligible US receivables, as defined, of the Clinical Lab and Life Science segments up to $8.0 million at defined eligibility percentages and provides for additional borrowings of $4.0 million for increased eligible assets. Debt issuance costs of $281 are being amortized over the life of the Credit Agreement. If the amount of borrowings outstanding under the revolving credit facility exceeds the borrowing base then in effect, or the Lender requires a reserve, the Company will be required to repay such borrowings in an amount sufficient to eliminate such excess. Interest on advances, payable monthly, is based on the three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%, In the event of any default, the interest rate may be increased 3.0% over the current rate. The facility also carries a non-utilization fee of 0.50% per annum, payable monthly, on the unused portion of the Credit Agreement. The Credit Agreement requires a minimum borrowing of $2.0 million. At January 31, 2015 and July 31, 2014, the borrowings under the Credit Agreement related to the Clinical Labs and Life Sciences receivables aggregated $3.0 million with an additional availability of $1.9 million at January 31, 2015.
	The Company’s obligations under the Credit Agreement are secured by primarily all the unencumbered U.S. assets of the Company, excluding buildings and intellectual property which the Lender has a negative pledge, and the capital stock of subsidiaries. The Credit Agreement includes customary affirmative and negative covenants and events of default and requires maximum levels of cash usage and minimum levels of liquidity, as defined, and provides for increased liquidity levels if operating results are not achieved. Negative covenants include among others, limitations on additional debt, liens, loans or investments, distributions, asset sales and affiliate transactions. Events of default include non-payment of principal and interest on debt outstanding, non-performance of covenants, material change in business, breach of representations, bankruptcy and insolvency, material judgments and changes in control. As of January 31, 2015, the Company is in compliance with the financial covenants.

Accrued_Liabilities_and_Other_

Accrued Liabilities and Other Current Liabilities	6 Months Ended
	Jan. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7 – Accrued Liabilities and Other Current Liabilities
	Accrued liabilities consist of the following:
		January 31,		July 31,
		2015		2014
	Legal fee expense		5,808		4,721
	Payroll, benefits, and commissions	$	3,116	$	4,959
	Professional fees		627		638
	Research and development		400		400
	Other		2,056		2,199
		$	12,007	$	12,917
	Other current liabilities consist of the following:
		January 31,		July 31,
		2015		2014
	Accrued legal settlement	$	400	$	400
	Installment loans		281		241
	Capital lease obligations		149		149
		$	830	$	790

Other_liabilities

Other liabilities	6 Months Ended
	Jan. 31, 2015
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Liabilities Disclosure [Text Block]	Note 8 – Other Liabilities
	Other liabilities consist of the following:
		January 31,		July 31,
		2015		2014
	Accrued legal settlement	$	1,200	$	1,600
	Capital lease obligations, net of short term		287		344
	Installment loans, net of short term		385		369
		$	1,872	$	2,313
	As of January 31, 2015, future minimum payments under the capital leases, net of interest of $45 aggregates $567, including a short term debt portion of $149 included in other current liabilities. Future minimum payments under the installment loans aggregate $575, including a short term portion of $281 included in other current liabilities. A total of $1.2 million was recorded as accrued legal settlement which is further discussed in Note 13 - Contingencies.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jan. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 – Stockholders’ Equity
	Controlled Equity Offering
	On March 28, 2013, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $20.0 million (the “Shares”). The Company will pay Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sales Agreement. The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The Shares were initially issued pursuant to the Company’s Registration Statement on Form S-3 which was declared effective on August 5, 2010 and a prospectus supplement, dated March 28, 2013, and more recently under the Company’s current Registration Statement on Form S-3 which was declared effective on August 13, 2013 and a prospectus supplement dated August 1, 2013, filed by the Company with the Securities and Exchange Commission (the “SEC”).
	During the six months ended January 31, 2015, the Company sold an aggregate of 1,126,804 shares of Common Stock under the Sales Agreement at an average price of $4.89 per share and received proceeds of approximately $5.3 million, net of expenses of $169. For the six months ended January 31, 2014, the Company sold an aggregate of 1,686,413 shares of Common Stock under the Sales Agreement at an average price of $2.59 per share and received proceeds of approximately $4.2 million, net of expenses of $131.
	On December 31, 2014, the Sales Agreement was amended in order for the Company to offer and sell, through Cantor, acting as agent, additional shares of Common Stock having an aggregate offering price of $20.0 million.  In connection with the amendment to the Sales Agreement, the Company also filed with the SEC a prospectus supplement dated December 31, 2014.  As of January 31, 2015, the Company still had Common Stock remaining available for sale pursuant to the Sales Agreement and the prior prospectus supplement dated August 1, 2013.
	Share-based compensation
	The Company has an incentive stock option plan (the “1999 Plan”), an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Incentive Plan”), which are more fully described in Note 10 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2014. The 2011 Plan, which is the only plan from which awards may now be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards.
	The amounts of share-based compensation expense recognized in the periods presented are as follows:
		Three months ended						Six months ended
		January 31,						January 31,
		2015			2014			2015		2014
	Stock options	$	91		$	63		$	176	$	110
	Restricted stock		14			46			27		102
		$	105		$	109		$	203	$	212
	The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:
		Three months ended						Six months ended
		January 31,						January 31,
		2015			2014			2015		2014
	Cost of clinical laboratory services	$	2		$	2		$	3	$	4
	Research and development		1			—			2		1
	Selling, general and administrative		102			107			198		207
		$	105		$	109		$	203	$	212
	0 excess tax benefits were recognized during the six month periods ended January 31, 2015 and 2014.
	Stock Option Plans
	The following table summarizes stock option activity during the six month period ended January 31, 2015:
		Options			Weighted			Weighted		Aggregate
					Average			Average		Intrinsic
					Exercise			Remaining		Value (000s)
					Price			Contractual
								Term
	Outstanding at July 31, 2014		1,155,910		$	5.03
	Awarded		383,873		$	3.57
	Exercised		—		$	—
	Cancelled or expired		(180,900	)	$	16.82
	Outstanding at end of period		1,358,883		$	3.06			3.0 years	$	602
	Exercisable at end of period		777,022		$	2.89		1.8 years		$	301
	As of January 31, 2015, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $0.7 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is twenty-one months.
	The intrinsic value of stock option awards that vested during the fiscal year represents the value of the Company’s closing stock price on the last trading day of the fiscal year in excess of the exercise price multiplied by the number of options that vested.
	Restricted Stock Awards
	A summary of the activity pursuant to the Company’s unvested restricted stock awards for the six months ended January 31, 2015 is as follows:
		Awards			Weighted
					Average
					Award Price
	Outstanding at July 31, 2014		42,502		$	5.74
	Awarded		3,000		$	5.62
	Vested		(8,087	)	$	(1.86	)
	Forfeited		(5,250	)	$	(3.31	)
	Unvested at end of period		32,165		$	7.09
	The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of January 31, 2015, there was approximately $0.1 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately eighteen months.
	The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 1,298,000 shares as of January 31, 2015.
	The fair value of the awards that vested during the six months ended January 31, 2015 and 2014 was $43 and $381, respectively.

Income_taxes

Income taxes	6 Months Ended
	Jan. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 10 - Income taxes
	At the end of each interim reporting period, the Company estimates its effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods.
	The Company’s effective tax rate benefit for the three months ended January 31, 2015 was 2.7% compared to a deminimus benefit during the three months ended January 31, 2014. The Company’s effective tax rate provision was deminimus for the six months ended January 31, 2015 and 2014. The tax provision or benefit for the periods was based on state, local and foreign taxes, net of the benefit for amortization of foreign intangibles. The Company’s effective tax rate for both periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit.
	The Company files a consolidated Federal income tax return. The Company files combined returns with California, Michigan and New York State and City for certain subsidiaries. Other subsidiaries file separate state and foreign tax returns. With few exceptions, the periods that remain subject to examination are fiscal years ended July 31, 2011 through July 31, 2014.

Royalty_and_licensing_income

Royalty and licensing income	6 Months Ended
	Jan. 31, 2015
Royalty And Licensing Income [Abstract]
Royalty And Licensing Income [Text Block]	Note 11 – Royalty and licensing income
	The Company’s Life Science segment has a license agreement with QIAGEN Gaithersburg Inc. (“Qiagen”) that began in 2005, whereby the Company earns quarterly royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the three months ended January 31, 2015 and 2014, the Company recorded royalty income under the agreement of approximately $0.6 million and $1.0 million respectively. During the six months ended January 31, 2015 and 2014, the Company recorded royalty income under the agreement of approximately $1.6 million and $2.6 million respectively.

Segment_reporting

Segment reporting	6 Months Ended
	Jan. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 12 – Segment reporting
	The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Company’s Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Company’s Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments.
	Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal fee expense specific to other segments’ activities has been allocated to those segments.
	Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended July 31, 2014.
	The following financial information represents the operating results of the reportable segments of the Company:
	Three months ended January 31, 2015
		Clinical			Life			Therapeutics			Other			Consolidated
		Labs			Sciences
	Revenues:
	Clinical laboratory services	$	14,725			—			—			—		$	14,725
	Product revenues		—		$	7,723			—			—			7,723
	Royalty and license fee income		—			644			—			—			644
			14,725			8,367			—			—			23,092
	Operating expenses:
	Cost of clinical laboratory services		9,246			—			—			—			9,246
	Cost of product revenues		—			3,818			—			—			3,818
	Research and development		—			635		$	199			—			834
	Selling, general and administrative		5,089			2,704			—		$	1,877			9,670
	Provision for uncollectible accounts receivable		658			(57	)		—			—			601
	Legal fee expense		41			(53	)		—			2,816			2,804
	Total operating expenses		15,034			7,047			199			4,693			26,973
	Operating income (loss)		(309	)		1,320			(199	)		(4,693	)		(3,881	)
	Other income (expense)
	Interest		(12	)		5			—			(42	)		(49	)
	Other		4			(29	)		—			8			(17	)
	Foreign exchange loss		—			(259	)		—			—			(259	)
	Income (loss) before income taxes	$	(317	)	$	1,037		$	(199	)	$	(4,727	)	$	(4,206	)
	Depreciation and amortization included above	$	357		$	555		$	1		$	22		$	935
	Share-based compensation included in above:
	Cost of clinical laboratory services	$	2			—			—			—		$	2
	Research and development		—		$	1			—			—			1
	Selling, general and administrative		12			3			—		$	87			102
	Total	$	14		$	4			—		$	87		$	105
	Capital expenditures	$	338		$	51		$	—		$	—		$	389
	Three months ended January 31, 2014
		Clinical			Life			Therapeutics			Other			Consolidated
		Labs			Sciences
	Revenues:
	Clinical laboratory services	$	13,848			—			—			—		$	13,848
	Product revenues		—		$	8,054			—			—			8,054
	Royalty and license fee income		—			1,026			—			—			1,026
			13,848			9,080			—			—			22,928
	Operating expenses:
	Cost of clinical laboratory services		9,292			—			—			—			9,292
	Cost of product revenues		—			3,865			—			—			3,865
	Research and development		3			543		$	286			—			832
	Selling, general and administrative		4,981			3,318			—		$	1,785			10,084
	Provision for uncollectible accounts receivable		920			(8	)		—			—			912
	Legal fee expense		142			15			—			1,339			1,496
	Total operating expenses		15,338			7,733			286			3,124			26,481
	Operating income (loss)		(1,490	)		1,347			(286	)		(3,124	)		(3,553	)
	Other income (expense)
	Interest		(11	)		3			—			(44	)		(52	)
	Other		9			(6	)		—			12			15
	Foreign exchange gain		—			20			—			—			20
	Income (loss) before income taxes	$	(1,492	)	$	1,364		$	(286	)	$	(3,156	)	$	(3,570	)
	Depreciation and amortization included above	$	355		$	621		$	2		$	24		$	1,002
	Share-based compensation included in above:
	Cost of clinical laboratory services	$	2			—			—			—		$	2
	Research and development		—			—			—			—			—
	Selling, general and administrative		9		$	5			—		$	93			107
	Total	$	11		$	5			—		$	93		$	109
	Capital expenditures	$	103		$	7		$	—		$	—		$	110
	The following financial information represents the operating results of the reportable segments of the Company:
Six months ended January 31, 2015
	Clinical			Life			Therapeutics			Other			Consolidated
	Labs			Sciences
Revenues:
Clinical laboratory services	$	30,547			—			—			—		$	30,547
Product revenues		—		$	15,725			—			—			15,725
Royalty and license fee income		—			1,644			—			—			1,644
		30,547			17,369			—			—			47,916
Operating expenses:
Cost of clinical laboratory services		19,376			—			—			—			19,376
Cost of product revenues		—			7,513			—			—			7,513
Research and development		—			1,183		$	442			—			1,625
Selling, general and administrative		10,157			5,853			—		$	3,945			19,955
Provision for uncollectible accounts receivable		1,189			(47	)		—			—			1,142
Legal		131			(51	)		—			5,190			5,270
Total operating expenses		30,853			14,451			442			9,135			54,881
Operating income (loss)		(306	)		2,918			(442	)		(9,135	)		(6,965	)
Other income (expense)
Interest		(39	)		7			—			(86	)		(118	)
Other		6			(35	)		—			31			2
Foreign exchange gain		—			(731	)		—			—			(731	)
Income (loss) before income taxes	$	(339	)	$	2,159		$	(442	)	$	(9,190	)	$	(7,812	)
Depreciation and amortization included above	$	714		$	1,113		$	2		$	44		$	1,873
Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—		$	2			—			—			2
Selling, general and administrative		21			3			—		$	174			198
Total	$	24		$	5			—		$	174		$	203
Capital expenditures	$	589		$	64		$	—		$	—		$	653
Six months ended January 31, 2014
	Clinical			Life			Therapeutics			Other			Consolidated
	Labs			Sciences
Revenues:
Clinical laboratory services	$	28,707			—			—			—		$	28,707
Product revenues		—		$	15,717			—			—			15,717
Royalty and license fee income		—			2,637			—			—			2,637
		28,707			18,354			—			—			47,061
Operating expenses:
Cost of clinical laboratory services		19,001			—			—			—			19,001
Cost of product revenues		—			7,712			—			—			7,712
Research and development		14			1,069		$	566			—			1,649
Selling, general and administrative		10,031			6,813			—		$	3,768			20,612
Provision for uncollectible accounts receivable		1,764			20			—			—			1,784
Legal		290			37			—			2,550			2,877
Total operating expenses		31,100			15,651			566			6,318			53,635
Operating income (loss)		(2,393	)		2,703			(566	)		(6,318	)		(6,574	)
Other income (expense)
Interest		(22	)		8			—			-100			(114	)
Other		27			21			—			28			76
Foreign exchange gain		—			317			—			—			317
Income (loss) before income taxes	$	(2,388	)	$	3,049		$	(566	)	$	(6,390	)	$	(6,295	)
Depreciation and amortization included above	$	710		$	1,262		$	6		$	49		$	2,027
Share-based compensation included in above:
Cost of clinical laboratory services	$	4			—			—			—		$	4
Research and development		—		$	1			—			—			1
Selling, general and administrative		19			9			—		$	179			207
Total	$	23		$	10			—		$	179		$	212
Capital expenditures	$	362		$	82		$	—		$	—		$	444

Contingencies

Contingencies	6 Months Ended
	Jan. 31, 2015
Loss Contingency [Abstract]
Contingencies Disclosure [Text Block]	Note 13 – Contingencies
	On June 7, 2004, the Company and Enzo Life Sciences, Inc., filed suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned subsidiary Tropix, Inc., which became Life Technologies, Inc. (NASDAQ:LIFE) and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on February 3, 2014. The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products, and other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four patents are commonly referred to as the “Ward” patents. On November 12, 2012, a jury in New Haven found that one of these patents (United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this infringement. On January 6, 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest on the full amount will also be awarded starting November 7, 2012 until the total award is satisfied. The final award to Enzo could be reduced or be subject to possible claims from third parties. On February 3, 2014, Life Technologies filed a notice of appeal and the case was argued before the Court of Appeals for the Federal Circuit on November 6, 2014. There can be no assurance that the Company will be successful in this litigation. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company.
	As of August 1, 2014, the Company was engaged in litigation in the United States District Court for the Southern District of New York against two parties (and certain of their related companies), Roche Diagnostic GmbH (“Roche”), as plaintiff and declaratory judgment defendant, and Molecular Probes, Inc. (“Molecular Probes”). These cases were commenced in May 2004 and May 2003, respectively. The Company has asserted similar (with some differences) causes of action against Roche and Molecular Probes in these two cases, with the exception of a breach of contract claim only asserted against Roche. Roche seeks a declaratory judgment of non-breach and patent invalidity, while Molecular Probes seeks a declaratory judgment of patent invalidity against the Company. Roche has also asserted tort claims against the Company. The two cases were consolidated for pre-trial purposes in 2004 and there has been extensive discovery. In 2011, Roche and Molecular Probes moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, those motions were granted in part and denied in part. In December 2012, Roche and Molecular Probes moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. On December 6, 2013, the Court granted in part and denied in part Roche’s summary judgment motion. On October 22, 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by January 30, 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling relating to two of the Company’s patents asserted against Roche. Roche dropped its tort claims during damages discovery. On January 30, 2014, Roche and the Company jointly moved the Court to extend the schedule for damages discovery until 50 days after the Court’s rulings on two pending motions concerning discovery. Also on December 6, 2013, the Court granted Molecular Probes’ motion for summary judgment dismissing the Company’s non-patent claims and its claims concerning one of its patents. The Company continues to assert patent infringement claims against Molecular Probes. On December 18, 2014, the Court ordered that damages discovery concerning the Company’s remaining patent claims and Molecular Probes’ counterclaims should be completed by March 31, 2015, and expert discovery should be completed by June 30, 2015. The Company’s former counsel, Greenberg Traurig LLP, is also engaged in litigation against the Company in the United States District Court for the Southern District of New York concerning Greenberg Traurig’s request for a charging lien relating to its representation of the Company in these two and other cases.
	On June 20, 2014 the Company, as plaintiff finalized and executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer Life Sciences, Inc.) (together, “PerkinElmer”), with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow pursuant to the agreement because of a former counsel’s motion requesting a charging lien for fees allegedly owed for past services rendered to the Company. Because the settlement proceeds are held in escrow, the Company did not include the settlement or any additional amounts which may be payable to the attorney in the financial statements as of and for the fiscal year ended July 31, 2014 or for the six months ended January 31, 2015.
	As previously disclosed, in 2012, the Company received a Subpoena Duces Tecum (the “Subpoena”) from the Department of Health and Human Services, Office of Inspector General (“OIG”). The Subpoena was issued as part of an investigation being conducted by the US Attorney’s Office for the Eastern District of New York in conjunction with the OIG. While a number of potential issues were raised initially by the government, the investigation came to focus primarily on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. The time period initially covered by the investigation was from 2004 through 2011. In response to the Subpoena, the Company cooperated with the government. On September 22, 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve this matter, in substantive form as disclosed in the Company’s fiscal quarter ended April 30, 2014. During the quarter ended April, 30, 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the Clinical Labs segment. The settlement amount will be paid with interest over a five-year period. As of January 31, 2015, the Company carried a balance of $0.4 million as other current liabilities and $1.2 million as a non-current liability. Under certain circumstances, the Company may be required to accelerate payments and/or pay up to an additional $1.5 million based upon (i) a favorable recovery and collection related to the judgment in the Life Technologies matter discussed above, (ii) receipt of additional capital greater than $10.0 million in a fiscal year (in that case, the Company is required to pay 20% of any amount over $10.0 million plus interest, or (iii) sale of the Company. The final settlement covers the time period 2004-2014.
	The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jan. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consist of the following:
		January 31,		July 31,
		2015		2014
	Raw materials	$	1,086	$	1,092
	Work in process		2,285		2,460
	Finished products		4,912		5,138
		$	8,283	$	8,690

Goodwill_and_intangible_assets1

Goodwill and intangible assets (Tables)	6 Months Ended
	Jan. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	The Company’s change in the net carrying amount of intangible assets, all of which is included in the Life Sciences segment is as follows:
		Gross			Accumulated			Net
					Amortization
	31-Jul-14	$	28,478		$	(20,370	)	$	8,108
	Amortization expense		—			(859	)		(859	)
	Foreign currency translation		(442	)		315			(127	)
	31-Jan-15	$	28,036		$	(20,914	)	$	7,122
Schedule of Intangible Assets [Table Text Block]	Intangible assets consist of the following:
		31-Jan-15									31-Jul-14
		Gross			Accumulated			Net			Gross		Accumulated			Net
					Amortization								Amortization
	Patents	$	11,027		$	(10,793	)	$	234		$	11,027	$	(10,775	)	$	252
	Customer relationships		12,343			(6,943	)		5,400			12,602		(6,565	)		6,037
	Website and acquired content		1,027			(1,027	)		—			1,037		(1,037	)		—
	Licensed technology and other		511			(422	)		90			537		(434	)		103
	Trademarks		3,128			(1,729	)		1,398			3,275		(1,559	)		1,716
	Total	$	28,036		$	(20,914	)	$	7,122		$	28,478	$	(20,370	)	$	8,108
Schedule of Useful Lives For Acquisitions [Table Text Block]	At January 31, 2015, information with respect to intangibles assets acquired is as follows:
			Useful life				Weighted average
			assigned				remaining useful life
			Years
	Customer relationships		8		15		5.5 years
	Trademarks					5	2.5 years
	Other intangibles		4		5		0.5 year

Accrued_Liabilities_and_Other_1

Accrued Liabilities and Other Current Liabilities (Tables)	6 Months Ended
	Jan. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities consist of the following:
		January 31,		July 31,
		2015		2014
	Legal fee expense		5,808		4,721
	Payroll, benefits, and commissions	$	3,116	$	4,959
	Professional fees		627		638
	Research and development		400		400
	Other		2,056		2,199
		$	12,007	$	12,917
Schedule of Other Current Liabilities [Table Text Block]	Other current liabilities consist of the following:
		January 31,		July 31,
		2015		2014
	Accrued legal settlement	$	400	$	400
	Installment loans		281		241
	Capital lease obligations		149		149
		$	830	$	790

Other_liabilities_Tables

Other liabilities (Tables)	6 Months Ended
	Jan. 31, 2015
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Schedule of Other Liabilities [Table Text Block]	Other liabilities consist of the following:
		January 31,		July 31,
		2015		2014
	Accrued legal settlement	$	1,200	$	1,600
	Capital lease obligations, net of short term		287		344
	Installment loans, net of short term		385		369
		$	1,872	$	2,313

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Jan. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The amounts of share-based compensation expense recognized in the periods presented are as follows:
		Three months ended						Six months ended
		January 31,						January 31,
		2015			2014			2015		2014
	Stock options	$	91		$	63		$	176	$	110
	Restricted stock		14			46			27		102
		$	105		$	109		$	203	$	212
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:
		Three months ended						Six months ended
		January 31,						January 31,
		2015			2014			2015		2014
	Cost of clinical laboratory services	$	2		$	2		$	3	$	4
	Research and development		1			—			2		1
	Selling, general and administrative		102			107			198		207
		$	105		$	109		$	203	$	212
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity during the six month period ended January 31, 2015:
		Options			Weighted			Weighted		Aggregate
					Average			Average		Intrinsic
					Exercise			Remaining		Value (000s)
					Price			Contractual
								Term
	Outstanding at July 31, 2014		1,155,910		$	5.03
	Awarded		383,873		$	3.57
	Exercised		—		$	—
	Cancelled or expired		(180,900	)	$	16.82
	Outstanding at end of period		1,358,883		$	3.06			3.0 years	$	602
	Exercisable at end of period		777,022		$	2.89		1.8 years		$	301
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	A summary of the activity pursuant to the Company’s unvested restricted stock awards for the six months ended January 31, 2015 is as follows:
		Awards			Weighted
					Average
					Award Price
	Outstanding at July 31, 2014		42,502		$	5.74
	Awarded		3,000		$	5.62
	Vested		(8,087	)	$	(1.86	)
	Forfeited		(5,250	)	$	(3.31	)
	Unvested at end of period		32,165		$	7.09

Segment_reporting_Tables

Segment reporting (Tables)	6 Months Ended
	Jan. 31, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following financial information represents the operating results of the reportable segments of the Company:
	Three months ended January 31, 2015
		Clinical			Life			Therapeutics			Other			Consolidated
		Labs			Sciences
	Revenues:
	Clinical laboratory services	$	14,725			—			—			—		$	14,725
	Product revenues		—		$	7,723			—			—			7,723
	Royalty and license fee income		—			644			—			—			644
			14,725			8,367			—			—			23,092
	Operating expenses:
	Cost of clinical laboratory services		9,246			—			—			—			9,246
	Cost of product revenues		—			3,818			—			—			3,818
	Research and development		—			635		$	199			—			834
	Selling, general and administrative		5,089			2,704			—		$	1,877			9,670
	Provision for uncollectible accounts receivable		658			(57	)		—			—			601
	Legal fee expense		41			(53	)		—			2,816			2,804
	Total operating expenses		15,034			7,047			199			4,693			26,973
	Operating income (loss)		(309	)		1,320			(199	)		(4,693	)		(3,881	)
	Other income (expense)
	Interest		(12	)		5			—			(42	)		(49	)
	Other		4			(29	)		—			8			(17	)
	Foreign exchange loss		—			(259	)		—			—			(259	)
	Income (loss) before income taxes	$	(317	)	$	1,037		$	(199	)	$	(4,727	)	$	(4,206	)
	Depreciation and amortization included above	$	357		$	555		$	1		$	22		$	935
	Share-based compensation included in above:
	Cost of clinical laboratory services	$	2			—			—			—		$	2
	Research and development		—		$	1			—			—			1
	Selling, general and administrative		12			3			—		$	87			102
	Total	$	14		$	4			—		$	87		$	105
	Capital expenditures	$	338		$	51		$	—		$	—		$	389
	Three months ended January 31, 2014
		Clinical			Life			Therapeutics			Other			Consolidated
		Labs			Sciences
	Revenues:
	Clinical laboratory services	$	13,848			—			—			—		$	13,848
	Product revenues		—		$	8,054			—			—			8,054
	Royalty and license fee income		—			1,026			—			—			1,026
			13,848			9,080			—			—			22,928
	Operating expenses:
	Cost of clinical laboratory services		9,292			—			—			—			9,292
	Cost of product revenues		—			3,865			—			—			3,865
	Research and development		3			543		$	286			—			832
	Selling, general and administrative		4,981			3,318			—		$	1,785			10,084
	Provision for uncollectible accounts receivable		920			(8	)		—			—			912
	Legal fee expense		142			15			—			1,339			1,496
	Total operating expenses		15,338			7,733			286			3,124			26,481
	Operating income (loss)		(1,490	)		1,347			(286	)		(3,124	)		(3,553	)
	Other income (expense)
	Interest		(11	)		3			—			(44	)		(52	)
	Other		9			(6	)		—			12			15
	Foreign exchange gain		—			20			—			—			20
	Income (loss) before income taxes	$	(1,492	)	$	1,364		$	(286	)	$	(3,156	)	$	(3,570	)
	Depreciation and amortization included above	$	355		$	621		$	2		$	24		$	1,002
	Share-based compensation included in above:
	Cost of clinical laboratory services	$	2			—			—			—		$	2
	Research and development		—			—			—			—			—
	Selling, general and administrative		9		$	5			—		$	93			107
	Total	$	11		$	5			—		$	93		$	109
	Capital expenditures	$	103		$	7		$	—		$	—		$	110
	Six months ended January 31, 2015
		Clinical			Life			Therapeutics			Other			Consolidated
		Labs			Sciences
	Revenues:
	Clinical laboratory services	$	30,547			—			—			—		$	30,547
Product revenues		—		$	15,725			—			—			15,725
Royalty and license fee income		—			1,644			—			—			1,644
		30,547			17,369			—			—			47,916
Operating expenses:
Cost of clinical laboratory services		19,376			—			—			—			19,376
Cost of product revenues		—			7,513			—			—			7,513
Research and development		—			1,183		$	442			—			1,625
Selling, general and administrative		10,157			5,853			—		$	3,945			19,955
Provision for uncollectible accounts receivable		1,189			(47	)		—			—			1,142
Legal		131			(51	)		—			5,190			5,270
Total operating expenses		30,853			14,451			442			9,135			54,881
Operating income (loss)		(306	)		2,918			(442	)		(9,135	)		(6,965	)
Other income (expense)
Interest		(39	)		7			—			(86	)		(118	)
Other		6			(35	)		—			31			2
Foreign exchange gain		—			(731	)		—			—			(731	)
Income (loss) before income taxes	$	(339	)	$	2,159		$	(442	)	$	(9,190	)	$	(7,812	)
Depreciation and amortization included above	$	714		$	1,113		$	2		$	44		$	1,873
Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—		$	2			—			—			2
Selling, general and administrative		21			3			—		$	174			198
Total	$	24		$	5			—		$	174		$	203
Capital expenditures	$	589		$	64		$	—		$	—		$	653
Six months ended January 31, 2014
	Clinical			Life			Therapeutics			Other			Consolidated
	Labs			Sciences
Revenues:
Clinical laboratory services	$	28,707			—			—			—		$	28,707
Product revenues		—		$	15,717			—			—			15,717
Royalty and license fee income		—			2,637			—			—			2,637
		28,707			18,354			—			—			47,061
Operating expenses:
Cost of clinical laboratory services		19,001			—			—			—			19,001
Cost of product revenues		—			7,712			—			—			7,712
Research and development		14			1,069		$	566			—			1,649
Selling, general and administrative		10,031			6,813			—		$	3,768			20,612
Provision for uncollectible accounts receivable		1,764			20			—			—			1,784
Legal		290			37			—			2,550			2,877
Total operating expenses		31,100			15,651			566			6,318			53,635
Operating income (loss)		(2,393	)		2,703			(566	)		(6,318	)		(6,574	)
Other income (expense)
Interest		(22	)		8			—			-100			(114	)
Other		27			21			—			28			76
Foreign exchange gain		—			317			—			—			317
Income (loss) before income taxes	$	(2,388	)	$	3,049		$	(566	)	$	(6,390	)	$	(6,295	)
Depreciation and amortization included above	$	710		$	1,262		$	6		$	49		$	2,027
Share-based compensation included in above:
Cost of clinical laboratory services	$	4			—			—			—		$	4
Research and development		—		$	1			—			—			1
Selling, general and administrative		19			9			—		$	179			207
Total	$	23		$	10			—		$	179		$	212
Capital expenditures	$	362		$	82		$	—		$	—		$	444

Net_loss_per_share_Details

Net loss per share (Details)	3 Months Ended		6 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014
Unvested Restricted Stock [Member]
Net loss per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	0	18,000	22,000
In the Money Stock Options [Member]
Net loss per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	411,000	0	438,000	0
Outstanding Options [Member]
Net loss per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	52,000	1,341,000	97,000	1,032,000

Supplemental_disclosure_for_st1

Supplemental disclosure for statement of cash flows (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Income Taxes Paid	$37	$17
Interest Paid	101	98
Installment Loans Financed Amount	57	154
Capital Lease Obligation Cost Basis	155
Adjustment to Additional Paid in Capital Stock Option Issued in Lieu of Cash Payment	$45

Inventories_Details_Schedule_o

Inventories (Details) - Schedule of inventory, current (USD $)	Jan. 31, 2015	Jul. 31, 2014
In Thousands, unless otherwise specified
Schedule of inventory, current [Abstract]
Raw materials	$1,086	$1,092
Work in process	2,285	2,460
Finished products	4,912	5,138
	$8,283	$8,690

Goodwill_and_intangible_assets2

Goodwill and intangible assets (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jul. 31, 2014
Goodwill and intangible assets (Details) [Line Items]
Goodwill	7,452	$7,452
Intangible Assets, Amortization Period [Member]
Goodwill and intangible assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	4 years 6 months

Goodwill_and_intangible_assets3

Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Jul. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Gross	$28,036		$28,478
Accumulated Amortization	-20,914		-20,370
Net	7,122		8,108
Amortization expense	-859	-928
Amortization expense	-859	-928
Life Sciences [Member]
Indefinite-lived Intangible Assets [Line Items]
Gross	28,036		28,478
Accumulated Amortization	-20,914		-20,370
Net	7,122		8,108
Amortization expense	-859
Amortization expense	-859
Foreign currency translation	-442
Foreign currency translation	315
Foreign currency translation	($127)

Goodwill_and_intangible_assets4

Goodwill and intangible assets (Details) - Schedule of intangible assets (USD $)	Jan. 31, 2015	Jul. 31, 2014
In Thousands, unless otherwise specified
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	$28,036	$28,478
Finite-lived intangible assets, Accumulated Amortization	-20,914	-20,370
Finite-lived intangible assets, Net	7,122	8,108
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,027	11,027
Finite-lived intangible assets, Accumulated Amortization	-10,793	-10,775
Finite-lived intangible assets, Net	234	252
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	12,343	12,602
Finite-lived intangible assets, Accumulated Amortization	-6,943	-6,565
Finite-lived intangible assets, Net	5,400	6,037
Website And Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	1,027	1,037
Finite-lived intangible assets, Accumulated Amortization	-1,027	-1,037
Licensed Technology And Other [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	511	537
Finite-lived intangible assets, Accumulated Amortization	-422	-434
Finite-lived intangible assets, Net	90	103
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	3,128	3,275
Finite-lived intangible assets, Accumulated Amortization	-1,729	-1,559
Finite-lived intangible assets, Net	$1,398	$1,716

Goodwill_and_intangible_assets5

Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions	6 Months Ended
	Jan. 31, 2015
Customer Relationships [Member] | Minimum [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	8 years
Customer Relationships [Member] | Maximum [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	15 years
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Weighted average remaining useful life	5 years 6 months
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	5 years
Weighted average remaining useful life	2 years 6 months
Other Intangible Assets [Member] | Minimum [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	4 years
Other Intangible Assets [Member] | Maximum [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	5 years
Other Intangible Assets [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Weighted average remaining useful life	6 months

Loan_Payable_Details

Loan Payable (Details) (USD $)	6 Months Ended
	Jan. 31, 2015	Jul. 31, 2014
Debt Disclosure [Abstract]
Line of Credit Facility Expiration Month and Year	Dec-16
Line of Credit Facility, Maximum Borrowing Capacity	$8,000,000
Line of Credit Facility Additional Borrowings Capacity	4,000,000
Unamortized Debt Issuance Expense	281,000
Debt Instrument, Description of Variable Rate Basis	three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%
LIBOR Rate Period	3 months
Debt Instrument, Basis Spread on Variable Rate	1.25%
Debt Instrument Margin on Variable Rate	4.00%
Debt Instrument Increase in Interest Rate on Default	3.00%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.50%
Line of Credit Facility Minimum Borrowings	2,000,000
Long-term Line of Credit	3,013,000	3,013,000
Line of Credit Facility, Remaining Borrowing Capacity	$1,900,000

Accrued_Liabilities_and_Other_2

Accrued Liabilities and Other Current Liabilities (Details) - Accrued liabilities (USD $)	Jan. 31, 2015	Jul. 31, 2014
In Thousands, unless otherwise specified
Accrued liabilities [Abstract]
Legal fee expense	$5,808	$4,721
Payroll, benefits, and commissions	3,116	4,959
Professional fees	627	638
Research and development	400	400
Other	2,056	2,199
	$12,007	$12,917

Accrued_Liabilities_and_Other_3

Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities (USD $)	Jan. 31, 2015	Jul. 31, 2014
In Thousands, unless otherwise specified
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items]
Other Liabilities Current	$830	$790
Accrued Legal Settlement [Member]
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items]
Other Liabilities Current	400	400
Installment Loans [Member]
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items]
Other Liabilities Current	281	241
Capital Lease Obligations [Member]
Accrued Liabilities and Other Current Liabilities (Details) - Other current liabilities [Line Items]
Other Liabilities Current	$149	$149

Other_liabilities_Details

Other liabilities (Details) (USD $)	Jan. 31, 2015	Jul. 31, 2014
Other liabilities (Details) [Line Items]
Other Liabilities, Current	$830,000	$790,000
Accrued Legal Settlement	1,200,000
Capital Lease Obligation [Member] | Clinical Labs [Member]
Other liabilities (Details) [Line Items]
Capital Leases, Future Minimum Payments, Interest Included in Payments	45,000
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments	567,000
Other Liabilities, Current	149,000
Installment Loans [Member] | Clinical Labs [Member]
Other liabilities (Details) [Line Items]
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments	575,000
Other Liabilities, Current	$281,000

Other_liabilities_Details_Sche

Other liabilities (Details) - Schedule of other current liabilities (USD $)	Jan. 31, 2015	Jul. 31, 2014
In Thousands, unless otherwise specified
Other liabilities (Details) - Schedule of other current liabilities [Line Items]
Other liabilities	$1,872	$2,313
Accrued Legal Settlement [Member]
Other liabilities (Details) - Schedule of other current liabilities [Line Items]
Other liabilities	1,200	1,600
Capital Lease Obligations [Member]
Other liabilities (Details) - Schedule of other current liabilities [Line Items]
Other liabilities	287	344
Installment Loans [Member]
Other liabilities (Details) - Schedule of other current liabilities [Line Items]
Other liabilities	$385	$369

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	6 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Dec. 31, 2014	Jul. 31, 2014
Stockholders' Equity (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$0.01			$0.01
Maximum Offering Price Under Sales Agreement	$20,000,000		$20,000,000
Percentage of Commission Payable on Equity Offering	3.00%
Average Sale Price of Stock (in Dollars per share)	$4.89	$2.59
Proceeds from Issuance of Common Stock	5,341,000	4,244,000
Stock Offering and Commissions Expenses	169,000	131,000
Excess Tax Benefit from Share-based Compensation, Financing Activities	0	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	21 months
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	100,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Remaining Contractual Terms	18 months
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	1,298,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$43,000	$381,000
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)	1,126,804	1,686,413

Stockholders_Equity_Details_Sc

Stockholders' Equity (Details) - Schedule of share-based compensation expense (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$105	$109	$203	$212
Options [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	91	63	176	110
Restricted Stocks [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$14	$46	$27	$102

Stockholders_Equity_Details_Sc1

Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$105	$109	$203	$212
Cost of Clinical Laboratory Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	2	2	3	4
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	1		2	1
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$102	$107	$198	$207

Stockholders_Equity_Details_Sc2

Stockholders' Equity (Details) - Schedule of stock option plans (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 31, 2015
Schedule of stock option plans [Abstract]
Outstanding at July 31, 2014	1,155,910
Outstanding at July 31, 2014	$5.03
Awarded	383,873
Awarded	$3.57
Cancelled or expired	-180,900
Cancelled or expired	$16.82
Outstanding at end of period	1,358,883
Outstanding at end of period	$3.06
Outstanding at end of period	3 years
Outstanding at end of period	$602
Exercisable at end of period	777,022
Exercisable at end of period	$2.89
Exercisable at end of period	1 year 292 days
Exercisable at end of period	$301

Stockholders_Equity_Details_Sc3

Stockholders' Equity (Details) - Schedule of restricted stock awards (USD $)	6 Months Ended
	Jan. 31, 2015
Schedule of restricted stock awards [Abstract]
Outstanding at July 31, 2014	42,502
Outstanding at July 31, 2014	$5.74
Awarded	$5.62
Awarded	3,000
Vested	-8,087
Vested	($1.86)
Forfeited	-5,250
Forfeited	($3.31)
Unvested at end of period	32,165
Unvested at end of period	$7.09

Income_taxes_Details

Income taxes (Details)	3 Months Ended	6 Months Ended
	Jan. 31, 2015	Jan. 31, 2015
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	2.70%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent		34.00%

Royalty_and_licensing_income_D

Royalty and licensing income (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014
Royalty and licensing income (Details) [Line Items]
Patent Expiration Date			24-Apr-18
Life Sciences [Member]
Royalty and licensing income (Details) [Line Items]
Royalty Revenue	$0.60	$1	$1.60	$2.60

Segment_reporting_Details

Segment reporting (Details)	6 Months Ended
	Jan. 31, 2015
Segment Reporting [Abstract]
Number of Reportable Segments	3

Segment_reporting_Details_Sche

Segment reporting (Details) - Schedule of segment reporting information, by segment (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014
Revenues:
Clinical laboratory services	$14,725	$13,848	$30,547	$28,707
Product revenues	7,723	8,054	15,725	15,717
Royalty and license fee income	644	1,026	1,644	2,637
Total revenues	23,092	22,928	47,916	47,061
Operating expenses:
Cost of clinical laboratory services	9,246	9,292	19,376	19,001
Cost of product revenues	3,818	3,865	7,513	7,712
Research and development	834	832	1,625	1,649
Selling, general and administrative	9,670	10,084	19,955	20,612
Provision for uncollectible accounts receivable	601	912	1,142	1,784
Legal fee expense	2,804	1,496	5,270	2,877
Operating income (loss)	-3,881	-3,553	-6,965	-6,574
Other income (expense)
Other	-17	15	2	76
Foreign exchange gain (loss)	-259	20	-731	317
Share-based compensation included in above:
Share-based compensation	105	109	203	212
Cost of Clinical Laboratory Services [Member] | Clinical Labs [Member]
Share-based compensation included in above:
Share-based compensation	2	2	3	4
Cost of Clinical Laboratory Services [Member] | Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	2	2	3	4
Cost of Clinical Laboratory Services [Member]
Share-based compensation included in above:
Share-based compensation	2	2	3	4
Research and Development Expense [Member] | Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation	1		2	1
Research and Development Expense [Member] | Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	1		2	1
Research and Development Expense [Member]
Share-based compensation included in above:
Share-based compensation	1		2	1
Selling, General and Administrative Expenses [Member] | Clinical Labs [Member]
Share-based compensation included in above:
Share-based compensation	12	9	21	19
Selling, General and Administrative Expenses [Member] | Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation	3	5	3	9
Selling, General and Administrative Expenses [Member] | Other Segments [Member]
Share-based compensation included in above:
Share-based compensation	87	93	174	179
Selling, General and Administrative Expenses [Member] | Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	102	107	198	207
Selling, General and Administrative Expenses [Member]
Share-based compensation included in above:
Share-based compensation	102	107	198	207
Total [Member] | Clinical Labs [Member]
Share-based compensation included in above:
Share-based compensation	14	11	24	23
Total [Member] | Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation	4	5	5	10
Total [Member] | Other Segments [Member]
Share-based compensation included in above:
Share-based compensation	87	93	174	179
Total [Member] | Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	105	109	203	212
Clinical Labs [Member]
Revenues:
Clinical laboratory services	14,725	13,848	30,547	28,707
Total revenues	14,725	13,848	30,547	28,707
Operating expenses:
Cost of clinical laboratory services	9,246	9,292	19,376	19,001
Research and development		3		14
Selling, general and administrative	5,089	4,981	10,157	10,031
Provision for uncollectible accounts receivable	658	920	1,189	1,764
Legal fee expense	41	142	131	290
Total operating expenses	15,034	15,338	30,853	31,100
Operating income (loss)	-309	-1,490	-306	-2,393
Other income (expense)
Interest	-12	-11	-39	-22
Other	4	9	6	27
Income (loss) before income taxes	-317	-1,492	-339	-2,388
Depreciation and amortization included above	357	355	714	710
Share-based compensation included in above:
Capital expenditures	338	103	589	362
Life Sciences [Member]
Revenues:
Product revenues	7,723	8,054	15,725	15,717
Royalty and license fee income	644	1,026	1,644	2,637
Total revenues	8,367	9,080	17,369	18,354
Operating expenses:
Cost of product revenues	3,818	3,865	7,513	7,712
Research and development	635	543	1,183	1,069
Selling, general and administrative	2,704	3,318	5,853	6,813
Provision for uncollectible accounts receivable	-57	-8	-47	20
Legal fee expense	-53	15	-51	37
Total operating expenses	7,047	7,733	14,451	15,651
Operating income (loss)	1,320	1,347	2,918	2,703
Other income (expense)
Interest	5	3	7	8
Other	-29	-6	-35	21
Foreign exchange gain (loss)	-259	20	-731	317
Income (loss) before income taxes	1,037	1,364	2,159	3,049
Depreciation and amortization included above	555	621	1,113	1,262
Share-based compensation included in above:
Capital expenditures	51	7	64	82
Therapeutics [Member]
Operating expenses:
Research and development	199	286	442	566
Total operating expenses	199	286	442	566
Operating income (loss)	-199	-286	-442	-566
Other income (expense)
Income (loss) before income taxes	-199	-286	-442	-566
Depreciation and amortization included above	1	2	2	6
Other Segments [Member]
Operating expenses:
Selling, general and administrative	1,877	1,785	3,945	3,768
Legal fee expense	2,816	1,339	5,190	2,550
Total operating expenses	4,693	3,124	9,135	6,318
Operating income (loss)	-4,693	-3,124	-9,135	-6,318
Other income (expense)
Interest	-42	-44	-86	-100
Other	8	12	31	28
Income (loss) before income taxes	-4,727	-3,156	-9,190	-6,390
Depreciation and amortization included above	22	24	44	49
Consolidated [Member]
Revenues:
Clinical laboratory services	14,725	13,848	30,547	28,707
Product revenues	7,723	8,054	15,725	15,717
Royalty and license fee income	644	1,026	1,644	2,637
Total revenues	23,092	22,928	47,916	47,061
Operating expenses:
Cost of clinical laboratory services	9,246	9,292	19,376	19,001
Cost of product revenues	3,818	3,865	7,513	7,712
Research and development	834	832	1,625	1,649
Selling, general and administrative	9,670	10,084	19,955	20,612
Provision for uncollectible accounts receivable	601	912	1,142	1,784
Legal fee expense	2,804	1,496	5,270	2,877
Total operating expenses	26,973	26,481	54,881	53,635
Operating income (loss)	-3,881	-3,553	-6,965	-6,574
Other income (expense)
Interest	-49	-52	-118	-114
Other	-17	15	2	76
Foreign exchange gain (loss)	-259	20	-731	317
Income (loss) before income taxes	-4,206	-3,570	-7,812	-6,295
Depreciation and amortization included above	935	1,002	1,873	2,027
Share-based compensation included in above:
Capital expenditures	$389	$110	$653	$444

Contingencies_Details

Contingencies (Details) (USD $)	1 Months Ended		6 Months Ended	21 Months Ended	12 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2012	Jun. 30, 2004	Jan. 31, 2015	Jun. 30, 2004	Jul. 31, 2014	Apr. 30, 2014	Jun. 20, 2014
Contingencies (Details) [Line Items]
Gain Contingency, Patents Allegedly Infringed upon, Number		6
Number of Licensee Patents			4
Gain Contingency, Patents Found Not Infringed upon, Number	1
Gain Contingencies Prejudgement Interest			$12.50
Loss Contingency, Number of Defendants				2
Extended Period of Schedule for Damages Discovery			50 days
Indemnification Agreement [Member]
Contingencies (Details) [Line Items]
Gain Contingency, Unrecorded Amount			48.5
Subpoena [Member] | Minimum [Member]
Contingencies (Details) [Line Items]
Litigation Settlement Period					2004
Amount of Additional Capital Receipt Condition for Litigation Settlement					10
Subpoena [Member] | Maximum [Member]
Contingencies (Details) [Line Items]
Litigation Settlement Period					2014
Subpoena [Member]
Contingencies (Details) [Line Items]
Investigation Period			The time period initially covered by the investigation was from 2004 through 2011
Estimated Litigation Settlement Amount						2
Period Over Which Settlement Amount Has to Be Paid						5 years
Estimated Litigation Liability, Current			0.4
Estimated Litigation Liability, Noncurrent			1.2
Additional Payment of Litigation Settlement Amount					1.5
Percentage of Additional Payment of Litigation Settlement Amount over Additional Capital Receipt					20.00%
Perkin Elmer [Member]
Contingencies (Details) [Line Items]
Escrow Deposit							$7